Updated Feb 9, 2016 03:59 PM ET
Prior Close: $34.98
Is MYGN a
Buy, Hold or Sell?
See its Zacks Rank in our free stock analysis report.
The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.
We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:
|Zacks Style Score||A|
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.
Zacks Scorecard Education - Learn more about the Zacks Scorecard
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The three scores are based on the trading styles of Growth, Value, and Momentum.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The way to access to the Zacks Rank
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.
320 WAKARA WAY
SALT LAKE CITY, UT 84108
|Fiscal Year End||June|
|Last Reported Quarter||12/31/2015|
|Next EPS Date||5/3/2016|
|Current Quarter EPS Consensus Estimate||0.38|
|Current Year EPS Consensus Estimate||1.66|
|Estimated Long-Term EPS Growth Rate||14.90|
|Next EPS Report Date||5/3/2016|
Price and Volume Information
|52 Week High||46.24|
|52 Week Low||30.30|
|20 Day Moving Average||1,338,405.75|
|Target Price Consensus||40.73|
|Shares Outstanding (millions)||69.77|
|Market Capitalization (millions)||2,414.11|
|Last Split Date||3/26/2009|
|Change in Payout Ratio||0.00|
|Last Dividend Payout / Amount||NA / $0.00|
|Trailing 12 Months||20.72|
|vs. Previous Year||12.50%|
|vs. Previous Quarter||9.76%|
|vs. Previous Year||4.83%|
|vs. Previous Quarter||5.34%|
|Price / Sales||3.23|